Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax offers a Therapeutic Strategy for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR+VEN), curren...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Leukemia
Asıl Yazarlar: Eide, Christopher A., Kurtz, Stephen E., Kaempf, Andy, Long, Nicola, Agarwal, Anupriya, Tognon, Cristina E., Mori, Motomi, Druker, Brian J., Chang, Bill H., Danilov, Alexey V., Tyner, Jeffrey W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484148/
https://ncbi.nlm.nih.gov/pubmed/32094466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0764-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller